Securities code: 300206 securities abbreviation: Edan Instruments Inc(300206) Announcement No.: 2022-002 Edan Instruments Inc(300206)
Annual performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. 1、 Performance forecast
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected performance: □ loss □ turnaround □ increase in the same direction √ decrease in the same direction
3. Performance forecast:
The current reporting period of the project is the same period of last year
Year on year decrease: 28% – 32%
Operating revenue operating revenue: 2318604200 yuan operating revenue: 1576650900 yuan – 1669395000 yuan
Shares attributable to listed companies decreased by 59% – 69% over the same period last year
East’s net profit: 653.5135 million yuan; Profit: 202.4776 million yuan – 267.7929 million yuan
After deducting non recurring profit and loss, it decreased by 63% – 73% over the same period of last year
Net profit of: 610610200 yuan; Profit: 164.8648 million yuan – 225.9258 million yuan
2、 Communication with accounting firms
The data related to the performance forecast is the result of the preliminary calculation of the company’s financial department and has not been audited by the accounting firm. However, the company has pre communicated with the annual report audit accounting firm on matters related to the performance forecast. There is no difference between the company and the accounting firm in the performance forecast of the reporting period.
Edan Instruments Inc(300206)
3、 Explanation of performance change reasons
1. During the reporting period, the revenue of the monitoring product line decreased significantly, resulting in a decrease in the overall revenue of the company compared with the same period last year; In addition to the monitoring product line, ultrasound product line, ECG product line, maternal and child product line, in vitro diagnosis product line and intelligent medical business have achieved positive growth. In 2020, due to the global outbreak of the epidemic, the sales of monitoring product lines directly related to the fight against the epidemic increased explosively, driving the increase of the overall revenue base in 2020. During the reporting period, the market sales of monitoring products have gradually returned to normal, resulting in a decline in the overall revenue during the reporting period.
In 2020, affected by the epidemic, the revenue increased abnormally. If the overall revenue data in this reporting period is compared with that in 2019, the growth rate is expected to be 53% – 62%, and the compound growth rate is still maintained at about 20%, maintaining a steady growth trend.
2. During the reporting period, the impact of the company’s non recurring profits and losses on the net profit is expected to be about 40 million yuan, mainly government subsidies.
3. During the reporting period, the impact of the provision for impairment of goodwill on the net profit is expected to be about 35 million yuan. 4. During the reporting period, the company continued to take Nippon cloud as the business core and continuously optimized the existing comprehensive information solutions by integrating new technologies and concepts such as cloud computing, Internet of things, artificial intelligence and 5g. At present, the launched solutions include: intelligent electrophysiology comprehensive solution, intelligent monitoring informatization comprehensive solution, intelligent mother and child integration platform solution Intelligent chest pain informatization comprehensive solution, intelligent ECG network informatization comprehensive solution and intelligent test informatization comprehensive solution. In particular, the penetration rate of smart ECG network informatization solutions in primary medical care and grade hospitals has increased steadily, which is expected to drive the rapid development of the company’s overall smart medical business in the future. 4、 Other relevant instructions
1. This performance forecast is the result of preliminary calculation by the financial department of the company.
2. The company will disclose specific financial data in detail in the 2021 annual report. Please pay attention to investment risks.
It is hereby announced.
Edan Instruments Inc(300206)
Board of directors January 20, 2002
